Becton, Dickinson and Company $BDX Shares Acquired by American Capital Advisory LLC

American Capital Advisory LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 55,050.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,412 shares of the medical instruments supplier’s stock after acquiring an additional 4,404 shares during the period. American Capital Advisory LLC’s holdings in Becton, Dickinson and Company were worth $694,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Auto Owners Insurance Co grew its stake in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the last quarter. Vanguard Group Inc. grew its position in Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after buying an additional 4,223,149 shares during the last quarter. State Street Corp increased its stake in Becton, Dickinson and Company by 0.8% in the 4th quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock valued at $2,714,871,000 after buying an additional 116,737 shares during the period. First Eagle Investment Management LLC raised its position in Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after buying an additional 1,651,592 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Becton, Dickinson and Company by 3.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock worth $1,841,083,000 after acquiring an additional 336,110 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Up 0.5%

Shares of Becton, Dickinson and Company stock opened at $156.36 on Wednesday. The company has a 50-day moving average of $148.08 and a two-hundred day moving average of $168.55. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market cap of $43.08 billion, a PE ratio of 39.58, a price-to-earnings-growth ratio of 11.01 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the previous year, the company earned $3.35 EPS. The company’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were given a $1.05 dividend. The ex-dividend date was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on BDX shares. Bank of America dropped their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. The Goldman Sachs Group lowered their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Finally, Argus decreased their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $180.29.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,188 shares of company stock valued at $765,120 in the last ninety days. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.